STALICLA
Lynn A Durham is an experienced executive with a robust background in business development and partnership management across various sectors, particularly in healthcare and technology. As the CEO and Founder of STALICLA since April 2017, Lynn has been pivotal in advancing innovative solutions in the field. Prior roles include Head of Partnerships at the University of Geneva, where Lynn led public-private partnerships to support translational research in Neurosciences and Oncology, and positions at IFJ AG, Tech Tour, and the World Economic Forum that focused on business engagement and development. Lynn holds multiple degrees, including a Master of Science in clinical trials and drug development from the University of Geneva, a Master's in Business Administration from NEOMA Business School, and a Master's in Economic History from Université Paris-Sorbonne.
STALICLA
STALICLA is a clinical stage, precision molecular neuroscience biotech company with a mature pipeline for patients with Neurodevelopmental Disorders (NDDs) and Neuropsychiatric disorders.STALICLA’s unique approach addresses a principal weakness in the drug development process for NDD’s and neuropsychiatric disorders: behavior is a terriblebiomarker. Clinical psychiatric and neurodevelopmental diagnoses encompass a broad diversity of underlying biology. This has contributed to drug development failure by diluting true responders in a population of patients with heterogeneous biology.STALICLA’s technology platform, DEPI, discovers biologically based endophenotypes within classical neuropsychiatric diagnostic groups. The AI/ML engine converges molecular data with human genetic information and non-behavioral clinical signs and symptoms, to define biologically related subgroups and create testable clinical hypotheses related to that biology. The DEPI platform has already completed several successful clinical validations, through the identification and biological validation of two distinct subgroups of patients with Autism Spectrum Disorder, ASD-Phenotype1 and ASD-Phenotype2, together with their predicted tailored treatment candidates (STP1 and STP2); as well as the blindly and retrospective calling “high” responder patients to previously failed drug candidates with high specificity, sensitivity, and positive predictive value.Further the completion of STP1 Phase 1b in 2022, STP1 will enter clinical Phase 2 in 2023; as well as STP2, a Phase 2 ready asset in licensed in Q4 ’22. Additionally, STALICLA will be advancing STP7, a recently in-licensed Phase 3 ready asset from Novartis, with strong potential for a neuropsychiatric indication, and whose clinical development will be fully financed by a non-dilutive funding to be announced in Feb.STALICLA is currently preparing its next stage of growth, to advance its pipelines and to scale its platform towards revenue generation.